Association of estimated pulse wave velocity with cardiovascular disease outcomes and all-cause death-a systematic review and meta-analysis.

Background: Methods: Studies published before February 2024 from PubMed, Embase, Cochrane Library, and Web of Science were searched. To ensure the completeness and timeliness of the included literature, a thorough re-search and update of the relevant literature were conducted on April 28, 2025. The data analysis was carried out utilizing STATA (V15.0). Results: A systematic review and meta-analysis of 20 studies involving 381,303 participants demonstrated that individuals with higher ePWV had significantly increased risks of total CV events (HR = 2.14, 95%CI: 1.70-2.71), CV mortality (HR = 3.64, 95%CI: 2.83-4.68), and all-cause mortality (HR = 1.85, 95%CI: 1.38-2.47). Specifically, for each 1 m/s increase in ePWV, the risks of these outcomes increased by 36%, 41%, and 37%, respectively. Analyses of population types further verified that elevated ePWV was independently associated with increased risks for all outcomes. For total CV events, the HRs were 1.79 (95%CI: 1.45-2.21) in the general population and 3.43 (95%CI: 2.62-4.49) in those with CVD. For CV mortality, the HRs were 4.90 (95%CI: 2.78-8.64) and 3.39 (95%CI: 2.56-4.49), respectively. For all-cause mortality, HRs were 2.28 (95%CI: 1.00-5.21) in the general population and 1.84 (95%CI: 1.20-1.42) in the CVD group. Moreover, each 1 m/s increase in ePWV was associated with a 27% and 54% increase in total CV event risk, a 28% and 54% increase in CV mortality, and a 47% and 30% increase in all-cause mortality in the general and CV populations, respectively. Conclusion: These findings highlight ePWV as a potential predictor of adverse health outcomes, warranting further research to establish reference values and compare with carotid-femoral pulse wave velocity. Systematic Review Registration: PROSPERO CRD42024536235.